1. A European subset analysis from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country‐specific features: results from psoriasis patients in Spain. (25th April 2017) Authors: Puig, L.; van de Kerkhof, P.C.M.; Reich, K.; Bachelez, H.; Barker, J.; Girolomoni, G.; Paul, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 7(2017) Page Start: 1176 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64‐week multinational randomized phase IV study in 1790 patients (PSO‐TOP). (1st July 2017) Authors: Reich, K.; Zschocke, I.; Bachelez, H.; de Jong, E.M.G.J.; Gisondi, P.; Puig, L.; Warren, R.B.; Ortland, C.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 177:Number 1(2017) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64‐week multinational randomized phase IV study in 1790 patients (PSO‐TOP). (6th June 2017) Authors: Reich, K.; Zschocke, I.; Bachelez, H.; de Jong, E.M.G.J.; Gisondi, P.; Puig, L.; Warren, R.B.; Ortland, C.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 177:Number 1(2017) Page Start: 197 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Antitumour necrosis factor‐α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. (1st March 2016) Authors: Sbidian, E.; Hotz, C.; Seneschal, J.; Maruani, A.; Amelot, F.; Aubin, F.; Paul, C.; Beylot Barry, M.; Humbert, P.; Dupuy, A.; Caux, F.; Dupin, N.; Modiano, P.; Lepesant, P.; Ingen‐Housz‐Oro, S.; Mahé, E.; Bachelez, H.; Chosidow, O.; Wolkenstein, P. Journal: British journal of dermatology Issue: Volume 174:Number 3(2016) Page Start: 667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Antitumour necrosis factor‐α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013. (22nd December 2015) Authors: Sbidian, E.; Hotz, C.; Seneschal, J.; Maruani, A.; Amelot, F.; Aubin, F.; Paul, C.; Beylot Barry, M.; Humbert, P.; Dupuy, A.; Caux, F.; Dupin, N.; Modiano, P.; Lepesant, P.; Ingen‐Housz‐Oro, S.; Mahé, E.; Bachelez, H.; Chosidow, O.; Wolkenstein, P. Journal: British journal of dermatology Issue: Volume 174:Number 3(2016) Page Start: 667 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. (1st September 2016) Authors: Egeberg, A.; Mallbris, L.; Warren, R.B.; Bachelez, H.; Gislason, G.H.; Hansen, P.R.; Skov, L. Journal: British journal of dermatology Issue: Volume 175:Number 3(2016) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. (20th June 2016) Authors: Egeberg, A.; Mallbris, L.; Warren, R.B.; Bachelez, H.; Gislason, G.H.; Hansen, P.R.; Skov, L. Journal: British journal of dermatology Issue: Volume 175:Number 3(2016) Page Start: 487 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials. (1st January 2019) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials3. (10th October 2018) Authors: Strober, B.E.; Gottlieb, A.B.; van de Kerkhof, P.C.M.; Puig, L.; Bachelez, H.; Chouela, E.; Imafuku, S.; Thaçi, D.; Tan, H.; Valdez, H.; Gupta, P.; Kaur, M.; Frajzyngier, V.; Wolk, R. Journal: British journal of dermatology Issue: Volume 180:Number 1(2019) Page Start: 67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Characteristics of patients with psoriasis with Psoriasis Area and Severity Index < 10 treated with biological agents: results from the French PsoBioTeq cohort. (1st November 2021) Authors: Beylot‐Barry, M.; Seneschal, J.; Tran, D.; Bachelez, H.; Beneton, N.; Dupuy, A.; Joly, P.; Jullien, D.; Mahé, E.; Paul, C.; Richard, M.‐A.; Sbidian, E.; Viguier, M.; Chosidow, O.; Tubach, F. Journal: British journal of dermatology Issue: Volume 185:Number 5(2021) Page Start: 1052 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗